← Back to Calendar
Live Company Data
NCM
Updated
3m ago
· Data: FMP
Current Price
$2.32
-90.34%
$-21.70 today
Day: $2.18 – $2.33
Market Cap
N/A
Shares out: 5.34M
Float: 5.29M
52-Week Range
Current price is at 2% of 52-week range
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Indication
Relapsed/refractory AML (R/R AML) — Phase 2B/3 MIRACLE trial interim readout
Key Notes
MIRACLE trial (Phase 2B/3) interim 45-subject data unblinding expected mid-2026 (estimated July 2026). 45th subject dosed March 23, 2026, triggering final countdown. Blinded preliminary CRc rate of 40% in first 30 subjects (30% CR; 10% CR with partial recovery). About 35% of subjects had failed prior venetoclax. AnnAraC = Annamycin + cytarabine. Next milestone: 90-subject full Part A unblinding expected Q3 2026. NDA rolling submission planned 2028 if pivotal data positive. Micro-cap (~$30M market cap). Cash runway into Q3 2026 — financing risk.
⚠️ Not Investment Advice: This information is provided for educational purposes only.
PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period,
issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on
historical base rates and do not account for drug-specific factors. Always consult a financial advisor
before making investment decisions.
Discussion
Share your analysis, research, or questions about this catalyst. No account required.